Literature DB >> 17582378

A highly sensitive fluorometric assay for determination of human coagulation factor XIII in plasma.

Kai Oertel1, Andreas Hunfeld, Edgar Specker, Christine Reiff, Rainer Seitz, Ralf Pasternack, Johannes Dodt.   

Abstract

Based on the iso-peptidase activity of human plasma FXIII, a novel fluorometric assay that determines FXIII concentrations in human plasma below 0.05 IU/ml is introduced. We considered a peptide sequence derived from alpha(2)-antiplasmin (n =12) to yield high sensitivity. Peptide Abz-NE(Cad-Dnp)EQVSPLTLLK exhibits a K(m) value of 19.8+/-2.8 microM and is used in a concentration of 50 microM. The assay design is suitable for measurements in cuvettes (1 ml volume) as well as for the microtiter plate (MTP) format (0.2 ml volume). It provides linear dose-response curves over a wide range of FXIII concentrations (0.05-8.8 IU/ml). The assay was validated with respect to precision, detection and quantitation limits, accuracy/specificity, linearity, and range. A comparison of the fluorometric assay with the photometric assay for FXIII determinations in plasma pools as well as single donor plasma revealed suitability of the fluorometric assay for FXIII determination in plasma of healthy individuals. FXIII concentrations in plasma samples of patients with severe FXIII deficiency are discussed in the context of FXIII antigen levels. These assays correlate well in the critical range below 0.1 IU/ml, whereas the photometric assay may overestimate residual FXIII activity in severe FXIII-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582378     DOI: 10.1016/j.ab.2007.05.011

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  10 in total

1.  Reversible activation of cellular factor XIII by calcium.

Authors:  Gunhild Klarskov Kristiansen; Mette Dahl Andersen
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

2.  Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase.

Authors:  Abdullah Akbar; Nicole M R McNeil; Marie R Albert; Viviane Ta; Gautam Adhikary; Karine Bourgeois; Richard L Eckert; Jeffrey W Keillor
Journal:  J Med Chem       Date:  2017-09-14       Impact factor: 7.446

3.  Recombinant factor XIII diminishes multiple organ dysfunction in rats caused by gut ischemia-reperfusion injury.

Authors:  Sergey B Zaets; Da-Zhong Xu; Qi Lu; Eleonora Feketova; Tamara L Berezina; Maryann Gruda; Inga V Malinina; Edwin A Deitch; Eva H N Olsen
Journal:  Shock       Date:  2009-06       Impact factor: 3.454

Review 4.  State of the art in factor XIII laboratory assessment.

Authors:  Michael A Durda; Alisa S Wolberg; Bryce A Kerlin
Journal:  Transfus Apher Sci       Date:  2018-08-04       Impact factor: 1.764

5.  Characterization of thrombin derived from human recombinant prothrombin.

Authors:  Ann Lövgren; Johanna Deinum; Steffen Rosén; Pia Bryngelhed; Per Rosén; Kenny M Hansson
Journal:  Blood Coagul Fibrinolysis       Date:  2015-07       Impact factor: 1.276

6.  Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.

Authors:  Navina L Chrobok; John G J M Bol; Cornelis A Jongenelen; John J P Brevé; Said El Alaoui; Micha M M Wilhelmus; Benjamin Drukarch; Anne-Marie van Dam
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

7.  Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).

Authors:  Ralf Pasternack; Christian Büchold; Robert Jähnig; Christiane Pelzer; Michael Sommer; Andreas Heil; Peter Florian; Götz Nowak; Uwe Gerlach; Martin Hils
Journal:  J Thromb Haemost       Date:  2019-10-23       Impact factor: 5.824

8.  Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.

Authors:  Martina Leitner; Christian Büchold; Ralf Pasternack; Nikolaus B Binder; Gary W Moore
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 9.  Current understanding in diagnosis and management of factor XIII deficiency.

Authors:  M Naderi; A Dorgalaleh; Sh Tabibian; Sh Alizadeh; P Eshghi; Gh Solaimani
Journal:  Iran J Ped Hematol Oncol       Date:  2013-10-22

10.  Structure-Based Design of FXIIIa-Blockers: Addressing a Transient Hydrophobic Pocket in the Active Site of FXIIIa.

Authors:  Martin Stieler; Christian Büchold; Marisa Schmitt; Andreas Heine; Martin Hils; Ralf Pasternack; Gerhard Klebe
Journal:  ChemMedChem       Date:  2020-04-07       Impact factor: 3.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.